India, Nov. 18 -- Regeneron Pharmaceuticals (REGN) announced that the U.S. FDA has approved Livsayis (cemdisiran) for adults with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis the predominant form of the disease.
Generalized myasthenia gravis (gMG) is a rare autoimmune disorder that causes muscle weakness and fatigue, affecting activities such as speaking, swallowing, breathing, and mobility. Symptoms can fluctuate significantly and may sometimes become life-threatening.
First siRNA Therapy for gMG
Livsayis is the first FDA-approved small interfering RNA (siRNA) therapy for generalized myasthenia gravis and the only approved treatment in the disease administered subcutaneously four times per year.
Th...